Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic
JP Bewersdorf, O Abdel-Wahab - Genes & Development, 2022 - genesdev.cshlp.org
Despite FDA approval of nine new drugs for patients with acute myeloid leukemia (AML) in
the United States over the last 4 years, AML remains a major area of unmet medical need …
the United States over the last 4 years, AML remains a major area of unmet medical need …
Understanding the continuum between high-risk myelodysplastic syndrome and acute myeloid leukemia
PD Zavras, I Sinanidis, P Tsakiroglou… - International journal of …, 2023 - mdpi.com
Myelodysplastic syndrome (MDS) is a clonal hematopoietic neoplasm characterized by
bone marrow dysplasia, failure of hematopoiesis and variable risk of progression to acute …
bone marrow dysplasia, failure of hematopoiesis and variable risk of progression to acute …
[HTML][HTML] Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax+ …
Allogeneic hematopoietic stem cell transplantation (SCT) after a patient with acute myeloid
leukemia (AML) achieves a remission from intensive chemotherapy (IC) is given with …
leukemia (AML) achieves a remission from intensive chemotherapy (IC) is given with …
[HTML][HTML] GITMO Registry study on allogeneic transplantation in patients aged≥ 60 years from 2000 to 2017: improvements and criticisms
Today, allogeneic stem cell transplantation (allo-SCT) can be offered to patients up to age
70 to 72 years and represents one of the most effective curative treatments for many …
70 to 72 years and represents one of the most effective curative treatments for many …
Venetoclax: a new partner in the novel treatment era for acute myeloid leukemia and myelodysplastic syndrome
Abstract Background Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
are two closely related blood cancers that are more frequent in older adults. AML is the most …
are two closely related blood cancers that are more frequent in older adults. AML is the most …
Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic …
Y Du, C Li, Z Zhao, Y Liu, C Zhang, J Yan - BMC cancer, 2023 - Springer
Background Currently, there is no standard treatment for managing relapse in patients with
acute myeloid leukemia and myelodysplastic syndrome (AML/MDS) after allogeneic …
acute myeloid leukemia and myelodysplastic syndrome (AML/MDS) after allogeneic …
An updated overview of the role of CYP450 during xenobiotic metabolization in regulating the acute myeloid leukemia microenvironment
C Sandoval, Y Calle, K Godoy, J Farías - International Journal of …, 2023 - mdpi.com
Oxidative stress is associated with several acute and chronic disorders, including
hematological malignancies such as acute myeloid leukemia, the most prevalent acute …
hematological malignancies such as acute myeloid leukemia, the most prevalent acute …
[HTML][HTML] Targeted Therapy With Venetoclax and Daratumumab as Part of HSCT Preparative Regimen in Children With Chemorefractory Acute Myeloid Leukemia
M Klimentova, L Shelikhova, M Ilushina… - … and Cellular Therapy, 2023 - Elsevier
The long-term outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in
chemorefractory acute myeloid leukemia (AML) remains suboptimal because of a high …
chemorefractory acute myeloid leukemia (AML) remains suboptimal because of a high …
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors
JP Bewersdorf, RM Shallis, A Derkach… - Leukemia & …, 2023 - Taylor & Francis
Abstract FLT3, IDH1 and IDH2 inhibitors as well as venetoclax in combination with
hypomethylating agents or low-dose cytarabine have expanded treatment options for …
hypomethylating agents or low-dose cytarabine have expanded treatment options for …
Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?
JP Bewersdorf, SF Huntington, AM Zeidan - Journal of the National …, 2023 - jnccn.org
Acute myeloid leukemia (AML) is the most common acute leukemia in adults in the United
States and has seen the approval of several novel agents over the past decade. Similar to …
States and has seen the approval of several novel agents over the past decade. Similar to …